Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Studies show the small molecule adjuvant increases IgG binding antibody responses.
July 7, 2020
By: Contract Pharma
Contract Pharma Staff
According to 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, preclinical studies reveal 7HP349, an oral integrin activator that promotes cell adhesion, significantly increases IgG binding antibodies with a vaccine targeting SARS-CoV-2 (COV2), the virus that causes COVID-19. The data also suggest 7HP349 can be used as an immunostimulant for any COVID-19 vaccine and has the potential not only to augment the vaccines’ effectiveness, but also accelerate immune system response, allow for dose sparing and reduce or eliminate the need for boosters. “We expect our cell adhesion agents will greatly enhance the efficacy of emerging vaccines against this coronavirus,” said 7 Hills Pharma president and CEO Upendra Marathi, Ph.D., MBA. “Although this approach is potentially applicable for all ages, we are targeting older subjects who are at greater risk because of their lower immune responses to vaccines.” Combatting the Pandemic 7HP349 is 7 Hills Pharma’s lead product candidate in a platform of patent-protected small molecule integrin activators that significantly enhance cell adhesion. The company is working with The University of Texas Health Science Center at Houston (UTHealth) to develop 7HP349 as an oral immunostimulant for COVID-19 and seasonal influenza vaccinations. In preclinical studies the product has shown effectiveness in augmenting influenza, tuberculosis, and Chagas vaccines, and has demonstrated a positive safety profile. “We believe there could be a strong positive response of 7HP349 to improve COVID-19 vaccination after a single dose,” said Jeffrey Actor, PhD, professor in the Department of Pathology at McGovern Medical School at UTHealth. To meet the pandemic manufacturing demands, 7 Hills Pharma also has partnered with Catalent Pharma Solutions, Eurofins Advinus, and Lipoid LLC, and developed a robust formulation and scalable manufacturing processes. “Our softgel site in St. Petersburg, Florida, has the capacity to manufacture up to 8 billion capsules annually while Catalent’s softgel network extends to nine other sites globally. Catalent is not only well-placed to meet the demands of a pandemic vaccination program, but is also proud to continue its partnership with 7 Hills Pharma on this important program,” commented Rickey Shelly, PhD, senior director of technology development at Catalent in St. Petersburg. “We are humbled by a remarkable translational team we have assembled to meet the urgent need for an effective COVID-19 vaccination, particularly in the elderly,” added Dr. Marathi. “We are now actively seeking collaborators with clinical-stage nucleic acid, inactivated, or vectored COVID-19 vaccines that may be enhanced with our adjuvant and we expect to initiate a Phase 1 trial of 7HP349 this fall.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !